HaloperidolA quick delirium screenDecember The alert warns bolt deadbreak connector IV haloperidol is contraindicated for those patients because of QT-prolongation risk. How successful is the alert? According to preliminary analysis, doctors seem to ignore it about half the time and offer no reason for that decision. But the other half of the time, doctors change their minds about using hxldol drug, haldol iv vs oral the dose ordered, or modify its method of haldol iv vs oral from IV to IM injection.
Haloperidol - an overview | ScienceDirect Topics
Oral to IV conversion approximate: Although cases have been reported even in the absence of predisposing factors, particular caution is advised in treating patients with other QT-prolonging conditions including electrolyte imbalance [particularly hypokalemia and hypomagnesemia], drugs known to prolong QT, underlying cardiac abnormalities, hypothyroidism, and familial long QT-syndrome.
As with all drugs used to treat schizophrenia, dosage should be individualized according to the needs and response of each patient.
Dosage adjustments, either upward or downward, should be carried out as rapidly as practicable to achieve optimum therapeutic control. To determine the initial dosage, consideration should be given to the patient's age, severity of illness, previous response to other antipsychotic drugs, and any concomitant medication or disease state. Debilitated or geriatric patients, as well as those with a history of adverse reactions to antipsychotic drugs, may require less HALDOL haloperidol.
The optimal response in such patients is usually obtained with more gradual dosage adjustments and at lower dosage levels. Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms.
Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory. Controlled trials to establish the safety and effectiveness of intramuscular administration in children have not been conducted.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If higher doses are given, ECG monitoring is recommended. Usual starting doses are 0. Switchover Procedure An oral form should supplant the injectable as soon as practicable. In the absence of bioavailability studies establishing bioequivalence between these two dosage forms the following guidelines for dosage are suggested.
For an initial approximation of the total daily dose required, the parenteral dose administered in the preceding 24 hours may be used. Since this dose is only an initial estimate, it is recommended that careful monitoring of clinical signs and symptoms, including clinical efficacy, sedation, and adverse effects, be carried out periodically for the first several days following the initiation of switchover. In this way, dosage adjustments, either upward or downward, can be quickly accomplished.
Depending on the patient's clinical status, the first oral dose should be given within 12—24 hours following the last parenteral dose. Medical Calculators - A thru Z.
Lab Values - A thru Z. This site complies with the HONcode standard for trustworthy health information: The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment.